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Abstract
Precursor T-cell lymphoblastic neoplasms are aggressive malignancies in need for more effective and specific therapeutic 
treatments. A significant fraction of these neoplasms harbor deletions on the locus 9p21, targeting the tumor suppressor 
CDKN2A but also deleting the aconitase 1 (ACO1) gene, a neighboring housekeeping gene involved in cytoplasm and 
mitochondrial metabolism. Here we show that reducing the aconitase activity with fluorocitrate decreases the viability 
of T-cell lymphoblastic neoplasia cells in correlation to the differential aconitase expression. The consequences of the 
treatment were evidenced in vitro using T-cell lymphoblastic neoplasia cell lines exhibiting 9p21 deletions and variable 
levels of ACO1 expression or activity. Similar results were observed in melanoma cell lines, suggesting a true potential 
for fluorocitrate in different cancer types. Notably, ectopic expression of ACO1 alleviated the susceptibility of cell lines to 
fluorocitrate and, conversely, knockdown experiments increased susceptibility of resistant cell lines. These findings were 
confirmed in vivo on athymic nude mice by using tumor xenografts derived from two T-cell lines with different levels of 
ACO1. Taken together, our results indicate that the non-targeted ACO1 deficiency induced by common deletions exerts a 
collateral cellular lethality that can be used as a novel therapeutic strategy in the treatment of several types of cancer.
Introduction
T-cell lymphoblastic neoplasms are aggressive hematological 
malignancies originated from precursor T lymphoblasts 
whose differentiation is arrested at different stages of mat-
uration into the thymus. They often manifest with extensive 
bone marrow and blood involvement (acute T-cell lympho-
blastic leukemia, T-ALL), or infrequently with less than 25% of 
lymphoblasts in the bone marrow or periphery (T-cell lympho-
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analyses suggest that T-LBL and T-ALL might be considered 
as two distinct diseases (2,3). Intensive chemotherapy treat-
ment has gradually improved the outcome of these patients. 
However, primary resistance or relapse occurs in a significant 
fraction of patients therefore indicating the need for new 
treatments (4,5).
Common genetic alterations of T-cell lymphoblastic neo-
plasms include heterozygous and homozygous 9p21 dele-
tions involving cell cycle regulators p16INK4a and p15INK4B 
encoded by the CDKN2A/B locus (4), but also many neighboring 
passenger genes (6). Notably, deletions at the 9p21 region are 
common events in many other human cancers including glio-
blastoma (7), breast cancer (8) and melanoma (9,10). Germline 
mutations in CDKN2A and homozygous deletions at the 
9p21 region are particularly common in familial melanoma 
(9,11,12).
It has been established that cancer cells may harbor critical 
point mutations or deletions in passenger or collateral genes 
encoding essential functions, which are not primarily involved 
in causing cancer but are able to generate cellular vulnerability 
providing new therapeutic strategies (13). Although the potential 
of synthetic lethality in clinical translation was promising, there 
are not many examples underlying this strategy. A seminal art-
icle by Muller et al. (7) reported the general principles whereby the 
partial functional redundancy with other paralog genes can be 
harnessed for detecting cancer vulnerabilities. In glioblastoma 
cells, they showed that the loss of enolase 1 (ENO1), which en-
codes the enzyme enolase, makes tumor cells dependent of 
ENO2 and as such, they were more sensitive than normal cells 
to the inhibition of ENO2. Two additional works reported that 
5-methylthioadenosine phosphorylase/CDKN2A-deleted can-
cers exhibited enhanced dependency on the protein arginine 
methyl transferase protein arginine N-methyltransferase 5 and 
its binding partner WDR77 (14,15). Recently, Dey et al. (16) have 
provided a new example of tumor-specific lethality in pancreatic 
cancer, when the common homozygous deletion of the tumor 
suppressor SMAD4 involves genomic deletion of the mitochon-
drial malic enzyme 2 (ME2).
Since 9p21 deletion is the most common in T-ALL/LBL, 
in this work we sought to identify within the region some 
metabolic-housekeeping gene exhibiting partial redundancy, 
for which any small-molecule inhibitor was available. In ac-
cordance with previous reports, 9p21 deletion encompasses 
the tumor suppressors CDKN2A and CDKN2B (both at 9p21.3) 
(17,18) but could also entail passenger genes such as aconitase 
1 (ACO1) gene at 9p21.1 (7,19). Interestingly, ACO1 shows a par-
tial functional redundancy with ACO2, another member of 
this family that is located elsewhere in the mouse and human 
genomes. Thus, ACO2 might compensate ACO1 deletion. 
Microarray-based Comparative Genomic Hybridization (aCGH) 
analysis in a sample series of T-LBL revealed the occurrence of 
9p21 deletions involving ACO1 that in turn entailed reduced 
expression of ACO1. Notably, the treatment with fluorocitrate 
(an aconitase activity inhibitor) of T-cell lines exhibiting dif-
ferent levels of ACO1 and ACO2 differentially affected their sur-
vival and proliferation. These results were confirmed in tumor 
xenografts and extended in cell lines derived from melanoma, 




Primary T-LBL samples were provided by the Biobanks integrated in the 
Spanish Hospital Biobanks Network (RetBioH; www.redbiobancos.es) 
and diagnosed according to the World Health Organization Classification 
of Hematological Malignancies and the European childhood lymphoma 
pathology panel recommendations (20). Institutional review board ap-
proval was obtained for these studies (references CEI 31-773 and CEI-70-
1260). The participants provided written informed consent in accordance 
with the Declaration of Helsinki.
Cell lines
JURKAT (derived from T-ALL) and HEK 293T (derived from kidney) 
cell lines were purchased from the American Type Culture Collection 
(Manassas, VA). SUP-T1 (derived from T-LBL), PEER and HPB-ALL (derived 
from T-ALL) cell lines were obtained from the Leibniz Institute Deutsche 
Sammlung von Mikroorganismen und Zellkulturen-German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany). SK-MEL-28 
and SK-MEL-19 (derived from melanoma) (21) were obtained from Dr. 
Marisol Soengas (Centro Nacional de Investigaciones Ocológicas). The ap-
proximate doubling time of every cell line is 48 h, except for HEK-293T and 
SK-MEL-19 whose doubling time is 24 h. American Type Culture Collection, 
Deutsche Sammlung von Mikroorganismen und Zellkulturen and Centro 
Nacional de Investigaciones Ocológicas routinely perform cell line au-
thentication using short tandem repeat profiling. Cell experimentation 
was always performed between 3 and 35 passages after thawing and cells 
were kept in culture not longer than 3 months. Mycoplasma tests were 
negative both at the beginning and at the end of experimentation.
Quantitative real-time–polymerase chain reaction 
(qRT–PCR)
RNA was extracted using the TriPure Reagent (Roche Applied Science, 
Indianapolis, IN) and quantified with NanoDrop™ One (Thermo Fisher 
Scientific, Waltham, MA). The amount of mRNA was determined by quan-
titative RT–PCR using the High-Capacity RNA-to-cDNA™ Kit (Applied 
Biosystems, Foster City, CA). Expression values were determined with Fast 
SYBR™ Green Master Mix (Applied Biosystems). Reactions were performed 
in triplicate with an Applied Biosystems 7300 Real-Time PCR system (Life 
Technologies, Carlsbad, CA). Expression values of the housekeeping genes 
(B2M and ACTB) in the same samples were used for normalization using 
the 2−ΔΔCT method. Oligonucleotides sequences are indicated in Table S1.
Western blot analysis
Proteins were extracted using Radioimmunoprecipitation assay lysis buffer 
and quantified with the Bicinchoninic acid Protein Assay (Thermo Fisher 
Scientific). Spectrophotometric absorbance at 560 nm was measured using 
a microplate reader iMARK (Bio-Rad, Hercules, CA). Proteins underwent elec-
trophoresis in sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
gels and transferred to polyvinylidene fluoride membranes using Trans-Blot® 
Turbo™ Transfer System (Bio-Rad, Hercules, CA). Primary antibodies: ACO1 
(developed and provided by Dr. Cuezva, CBMSO, Spain), ACO2 (#6922), Cleaved 
Caspase-3 (Asp175) (#9661), Caspase-3 (#9662), PARP (#9542) (Cell Signaling, 
Danvers, MA), IREB2 (IRP-2 (7H6) sc-33682) (Santa Cruz Biotechnology, Inc., 
Dallas, TX), ANTI-FLAG (F3165), β-Actin (A5441) and α-Tubulin (T9026) (Sigma–
Aldrich, San Luis, MO). Secondary antibodies: antirabbit and antimouse 
IgGs (#7054 and #7056) (Cell Signaling). Peroxidase activity was analyzed 
using Western Bright ECL Detection System (Advansta, Menlo Park, CA). 
ImageQuant LAS 4000 (GE Healthcare Bio-Sciences, Piscataway, NJ) was used 
for image acquisition and the Scion Image Software (Scion Corporation, NIH, 
Frederick, MD) for band densitometry.
Aconitase activity assay
Cytosolic (c-aconitase, ACO1) and mitochondrial (m-aconitase, ACO2) 
aconitase activities were determined using the Aconitase Activity Assay 
Abbreviations 
qRT–PCR quantitative real-time–polymerase 
chain reaction
T-ALL acute T-cell lymphoblastic leukemia
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Kit (Sigma–Aldrich). In brief, 20  × 106 cells were centrifuged at 800g for 
10  min at 4°C to remove insoluble material. The supernatant was used 
for the c-aconitase assay. For the m-aconitase assay, the supernatant was 
centrifuged at 20 000g for 15 min at 4°C. Then, the pellet was dissolved in 
0.1 ml cold Assay Buffer and sonicated for 20 s. Activity assay was then 
performed according to the manufacturer’s instructions.
Microarray-based aCGH
aCGH analyses were carried out by NIMGenetics (New Integrated Medical 
Genetics, Madrid, Spain). Purified DNA from primary samples and cell 
lines were hybridized against the Human Genome CGH 44 kb microarrays 
(Agilent Technologies, Palo Alto, CA) version B, spanning through the en-
tire human genome at a median resolution of around 43 kb (24 kb me-
dian probe spacing in Refseq). A commercially available male DNA sample 
(Promega, Madison, WI) was used as reference. Microarray data analyses 
were performed with InSilicoArray CGH software-smoothing methods in-
cluded in gene expression profile analysis suite (http://gepas.bioinfo.cipf.
es). We considered heterozygous deletions (including monosomy) when 
the copy number variation was around −0.5 and homozygous deletions 
when the copy number variation was −1.
Ectopic expression of ACO1
Ectopic expression of ACO1 was performed in SUP-T1 by trans-
fecting these cells with a plasmid vector harboring the cDNA of 
ACO1 in frame with 3 tandem FLAG epitope tag in the C-terminus. 
Empty vector (pRP[Exp]-EF1A>3xFLAG/{Stuffer_300bp}) and pRP[Exp]-
EF1A>hACO1[NM_002197.3]/3xFLAG vectors were purchased from 
VectorBuilder (Chicago, IL). 15  × 106 cells were resuspended in 400  µl of 
Roswell Park Memorial Institute and electroporated with 20 µg of plasmid 
in three pulses of 5 ms at 270 V, 2000 µF and 2000 Ω (Gene Pulser MXcell™ 
Electroporation System, Bio-Rad).
Knockdown experiments
Transient ACO1 silencing was performed by transfecting JURKAT cells 
with MISSION shRNA for ACO1. pLKO.1-Puro non-target shRNA control, 
pLKO.1-Puro ACO1 shRNA-3 (clone TRCN0000056557) and ACO1 shRNA-4 
(clone TRCN0000333172) vectors were purchased from Sigma–Aldrich. 10 × 
106 cells were resuspended in 500 µl of Roswell Park Memorial Institute 
and electroporated with 40 µg of plasmid in two pulses of 10 ms at 300 
V, 2000  µF and 2000  Ω (Gene Pulser MXcell™ Electroporation System, 
Bio-Rad).
Cancer cell xenografts and tumor production
Four-week-old female athymic Nude-Foxn1nu mice were purchased from 
ENVIGO (Cambridgeshire, UK) and maintained under specific pathogen-
free conditions in the Animal Facility of the Centre of Molecular Biology 
Severo Ochoa (CBMSO, Madrid, Spain), according to the European 
Commission Guidelines (Directive 86/609/CEE) on the use of laboratory 
animals. After 1-week acclimatization before the experiment, subcuta-
neous tumor xenografts were established by injection of 5 × 106 SUP-T1 
cells stably expressing luciferase into one flank of the animals (n = 6). Cells 
were resuspended in 50  µL Roswell Park Memorial Institute and mixed 
with 50 µL Corning Matrigel Matrix (Corning, Bedford, MA) before injec-
tion. Tumor volume was evaluated by bioluminescence acquisition of an-
esthetized mice (isofluorane gas, 1.5%, Abbott, Madrid, Spain) using an IVIS 
Lumina II (Caliper Life Sciences, Waltham, MA) after intraperitoneal injec-
tion of 150 mg/kg of body weight of d-luciferin (Promega). The luminescent 
signal was quantified with the Living Image 3.2 software and expressed as 
photons/s (average radiance). Animals were scarified for humane reasons 
when tumors were 15 mm in diameter (experimental end point).
These procedures have the approval of the Community of 
Madrid (PROEX 22/15), the Ethic Committee of the Spanish National 
Research Council (CSIC; 308/2015) and the Ethics Committee of Animal 
Experimentation (CEEA) of the Centre of Molecular Biology Severo Ochoa 
(Madrid, Spain) (CEEA-CBMSO-23/191).
Fluorocitrate treatments
Aconitase inhibition was performed by treatments with fluorocitrate, a 
specific inhibitor of the Krebs’ cycle (22). It has been estimated that the 
concentration of fluorocitrate needed to inactivate 50% of the aconitase 
activity in fresh kidney mitochondria was 24  µM and that treatment 
of sonicated mitochondria with 60  µM fluorocitrate is able to reduce 
aconitase activity by up to 20% (23).
Fluorocitrate solution was prepared as indicated by Shang et al. (24) 
in a vehicle solution. Briefly, 240  mg of dl-fluorocitric acid barium salt 
(Sigma–Aldrich) was dissolved in 30 ml of 0.1 M HCl. Ba2+ was precipitated 
by adding 90 drops of Na2SO4 (0.1 M) and then, 60 ml Na2HPO4 (0.1 M). The 
suspension was then centrifuged at 1000g for 5 min. The supernatant was 
diluted with 0.9% NaCl to the final concentration of 2 mM and pH 6.68.
Cell lines were treated with fluorocitrate at concentrations ranging 
from 25 to 500 µM, using the vehicle as a reference (0 µM). Cells were col-
lected at 24, 48 and 72 h after treatment to perform cell viability and pro-
liferation analyses. Cells transfected with a plasmid vector harboring the 
cDNA of ACO1 or shRNA for ACO1 were treated with fluorocitrate 24 h after 
transfection and collected 24 h after treatment to perform cell viability 
and proliferation analyses. Xenografts mice were treated with 60 mg/kg 
of body weight fluorocitrate, once a day, 5 days a week, starting 1 week 
after inoculation and until experimental end point. Brain, kidney, liver and 
spleen biopsies were collected from killed mice and frozen for histological 
analyses. Samples were fixed with 10% formalin for 2  h, cryoprotected 
with 30% sucrose in phosphate buffer saline for 24 h and embedded in 
Tissue-Tek® O.C.T™ Compound (Sakura Finetek Europe B.V., Alphen aan 
den Rijn, The Netherlands). Sections of 3  µm were stained with hema-
toxylin and eosin. Coded slides were studied under the microscope by a 
pathologist unaware of the codes meaning. Potential pathological changes 
in the tissues were recorded in a blinded fashion.
Cell death analysis
Cell death was determined as the number of cells stained with propidium 
iodine using a FACSCalibur cytometer (Becton Dickinson, San Diego, CA). 
Data were analyzed by using FlowJo software (TreeStar, Inc., Ashland, OR).
Cell viability and proliferation
Cell viability was determined using Cell Proliferation Kit I (MTT) (Roche). 
Spectrophotometric absorbance at 560 nm with a reference wavelength 
of 750 nm was measured using the microplate reader iMARK (Bio-Rad).
Soft agar colony formation assay
A colony formation assay was performed for semiquantitative evaluation 
of anchorage-independent growth of melanoma cells lines in response to 
fluorocitrate treatment. 0.5 × 104 cells were mixed with 0.7% soft agar in 
Dulbecco’s modified Eagle’s medium with increasing fluorocitrate concen-
trations (25–500 µM), poured onto slightly solid 1% soft agar in medium 
with fluorocitrate and cultured for a week. Colonies formed in the soft 
agar were stained with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromid) labeling reagent (Roche) for 24 h at 37°C (with CO2). 
Plates were photographed and colonies were quantified using ImageJ 
Software (NIH, Frederick, MD).
Statistical analyses
Student’s t-test was used to compare results the means from different 
analyses (qRT–PCR, western blot) from at least three independent experi-
ments. After these analyses, we checked the expression data set for nor-
mality distribution using the Shapiro–Wilk test and the homogeneity of 
variances by Levene’s test. Pearson’s correlation coefficient and tests were 
used to determine the statistical correlation between two variables. All 
statistical analyses were performed using GraphPad Prism 7 (version 7.0; 
GraphPad Software, San Diego, CA). Tests with P values below 0.05 were 
considered statistically significant.
Results
ACO1 is a candidate gene for 9p21 deletions in T-cell 
lymphoblastic neoplasia
On the basis of the information provided by Muller et al. (7) ACO1 
was included in a curated list of candidate housekeeping genes 
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with paralog genes located elsewhere in the genome and proven 
targets of small molecules with a potential use in therapy. ACO1 
is a housekeeping gene encoding a bifunctional cytosolic protein 
that catalyzes the conversion of citrate to isocitrate (UniProtKB/
Swiss-Prot ACOC_HUMAN, P21399) and is involved in the 9p21 
deletion.
Given that 9p21 deletions are a common feature of T-cell 
lymphoblastic neoplasia, we first evaluated the involvement of 
ACO1 copy number variations (deletions) in primary T-LBL sam-
ples using microarray-based aCGH. The analysis of a sample 
series consisting of 19 primary T-LBLs revealed frequent 9p21 
causal deletion involving the CDKN2A locus (8/19, 42.1%), and 
one of them entailing the ACO1 locus at 9p21.1 (Figure 1A). ACO1 
paralog genes, ACO2 and IREB2, located elsewhere in the human 
genome, did not exhibit copy number variations.
In search of an in vitro model, we then investigated a panel 
of cell lines derived from T-cell lymphoblastic neoplasms. aCGH 
revealed that SUP-T1 cells experienced a mosaic monosomy 
affecting the entire chromosome 9. JURKAT cells have a causal 
homozygous deletion at 9p21.3 that does not involve ACO1 locus 
(Figure 1B). HPB-ALL cells do not have any disruption involving 
chromosome 9.  None of the cells analyzed exhibited chromo-
some 22 or chromosome 15 copy number alterations involving 
ACO2 or IREB2 loci, respectively.
ACO1, ACO2 and IREB2 expression and activity in 
T-cell lymphoblastic neoplasia cell lines
The expression levels of ACO1, ACO2 and IREB2 were analyzed in 
four cell lines derived from T-cell lymphoblastic neoplasms. SUP-
T1 showed the lowest levels of ACO1 and ACO2 expression (both 
at mRNA and protein levels). In contrary, JURKAT and PEER cells 
exhibited the highest levels of ACO1 and ACO2 expression. PEER 
and SUP-T1 cells expressed the lowest amount of IREB2 protein, 
which has not aconitase activity. Surprisingly, HPB-ALL cells ex-
hibited low levels of ACO1 protein despite its high level of ACO1 
Figure 1. Ideograms of microarray-based aCGH analyses (A and B) and evaluation of aconitase expression and activity in cell lines derived from T-cell lymphoblastic 
neoplasms (C–E). (A) Heterozygous deletion of 66.30 Mb (black bar) in the short arm of chromosome 9 (9p24.2p11.2) represented in a primary T-LBL sample (730T). This 
deletion affects more than 400 genes including ACO1 (9p21.1). In addition, a homozygous deletion of 0.12 Mb at 9p21.3 involved CDKN2A, CDKN2B and CDKN2B-AS1 
genes. (B) Copy number variations at 9p21 in two selected cell lines. JURKAT cells present a homozygous deletion of 2.11 Mb at the short arm (9p21.3) including 21 genes 
(ACO1 excluded). SUP-T1 cells present a mosaic monosomy of the entire chromosome affecting ACO1. (C) Relative mRNA levels of the three members of the aconitase 
family determined by qRT–PCR in the T-cell lines. Data represent the mean ± standard deviation (SD) of three independent experiments normalized with respect to 
the average value of all cell lines. (D) Representative western blot images of ACO1, ACO2 and IREB2. Numbers below each line result from densitometry analysis. (E) 
Cytosolic (ACO1) and mitochondrial (ACO2) aconitase activities in cell lines derived from T-cell lymphoblastic neoplasms. One unit indicates the amount of enzyme 
that will isomerize 1 µM of citrate to isocitrate per minute at pH 7.4 at 25°C. Data represent the mean ± standard deviation (SD) of three independent experiments. 
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mRNA, suggesting some unknown post-transcriptional regu-
latory mechanism (Figure 1C and D). We determined aconitase 
enzymatic activity in the four cell lines, separating cytosolic 
aconitase (attributable to ACO1) from mitochondrial aconitase 
(due to ACO2). Our results indicated that ACO1 activity was 
lower in SUP-T1 and HPB-ALL cell lines than in JURKAT and PEER 
(Figure 1E), in line with protein levels revealed by western blot.
The aconitase inhibitor fluorocitrate induces 
a cytotoxic effect of variable degree in T-cell 
lymphoblastic neoplasia cell lines
We sought to explore the effect of pharmacological treatments 
over T-cell lines using fluorocitrate and oxalomalate as two 
small molecules capable of inhibiting aconitase activity. In the 
cell, fluorocitrate is converted to fluoro-cis-aconitate and then to 
4-hydroxy-trans-aconitate, which binds to protein aconitases to 
inhibit their enzyme activity (25). On the other hand, oxalomalate 
is a powerful competitive inhibitor of ACO2 (26) that also cause a 
decrease in the iron-responsive element of IREB2 (27).
The assessment of propidium iodide positivity by flow 
cytometry revealed that the treatment with oxalomalate did not 
produce any significant cell response (data not shown). However, 
the treatment with fluorocitrate induced a substantial increase in 
the levels of cell death in SUP-T1 only 24 h after treatment and 
with concentrations as low as 25 µM (Figure 2A), as well as a sig-
nificant reduction in the percentage of living cells, as determined 
using a cell survival/proliferation approach (MTT) (Figure 2B).
The response to fluorocitrate was significantly different 
among cell lines, as reflected by the percentage of propidium 
iodine positive cells and MTT values (Figure 2C). Cell lines ex-
hibiting lower ACO1 levels were more sensitive to cell death in-
duction by fluorocitrate (particularly SUP-T1), which manifested 
with a significantly reduced percentage of living cells after 
treatment.
Taken together, our results indicate that reduced levels and 
activity of ACO1 make SUP-T1 cells significantly more vulner-
able to fluorocitrate at low concentrations of the drug.
Next, we sought to elucidate whether fluorocitrate-induced cell 
death could be attributed to apoptosis. For such purpose, two key 
apoptotic proteins were evaluated by western blot in two cell lines, 
one susceptible to the treatment (SUP-T1) and the other resistant 
(JURKAT). Whereas JURKAT cells showed no evidence of apoptosis, 
proteolytic activation of caspase 3 and poly(ADP-ribose) poly-
merase-1 (PARP) in SUP-T1 cells was already detectable 24 h after 
treatment with 25 µM of fluorocitrate. These findings indicate that 
fluorocitrate-induced cell death in SUP-T1 cells might be, at least in 
part, attributed to apoptosis (Figure 2D).
The response of tumor cells to fluorocitrate relies on 
ACO1 levels
To further confirm whether ACO1 level is the key factor in 
determining the response of tumor cells to fluorocitrate, we 
overexpressed ACO1 in SUP-T1 cells and we silenced endogenous 
ACO1 in JURKAT cells (Figure 3A and B). Overexpression of ACO1 
protected SUP-T1 cells from the cytotoxic effect of fluorocitrate 
(Figure 3C) whereas knockdown of ACO1 increased the sensi-
tivity of JURKAT cells to the drug (Figure 3D). These results sup-
port the role of ACO1 level and activity in the vulnerability of 
T-cell lymphoblastic neoplasia cell lines to fluorocitrate.
In vivo reduction of tumor growth by fluorocitrate
To study the potential of fluorocitrate as a therapy for cancer pa-
tients exhibiting ACO1 deficiency in the tumor cells, we tested the 
ability of fluorocitrate to reduce the tumor growth in vivo using 
xenografts. Athymic nude-Foxn1nu mice bearing SUP-T1-derived 
tumor xenografts were treated with 60 mg/kg of fluorocitrate or 
vehicle 5 days a week for 2 weeks. SUP-T1 cells developed aggres-
sive tumors that did not allow for longer treatments. Fluorocitrate 
induced a significant reduction of tumor growth at day 15 (Figure 
4) in comparison with vehicle. The dosage of fluorocitrate was 
well tolerated by the animals, which showed normal physical 
activity and behavior and no symptoms of toxicity. In addition, 
no pathological changes were detected in tissue sections from 
brain, liver, kidney and spleen (Supplementary Figure S1, avail-
able at Carcinogenesis Online). These results support the use of 
fluorocitrate as a specific therapy to kill tumor cells in cancer 
patients with ACO1 deficiency.
ACO1 levels determine the vulnerability of 
melanoma cells to fluorocitrate
Since homozygous deletions at the 9p21 region are common in 
other tumor types, we checked whether low ACO1 levels also 
induce tumor susceptibility in melanoma. We selected two cell 
lines derived from melanoma (SK-MEL-28 and SK-MEL-19) ex-
hibiting significant differences in ACO1 copy number. aCGH 
revealed that SK-MEL-19 cells suffered a partial monosomy 
affecting the cytobands 9p22.3-9p13.1 that includes the ACO1 
gene, whereas SK-MEL-28 does not harbor any deletions af-
fecting chromosome 9 (Figure 5A). Accordingly, SK-MEL-19 
showed a significant reduction in ACO1 expression and activity 
(Figure 5B–D). Using a cell proliferation assay, we evidenced 
that SK-MEL-19 cell line was significantly more sensitive to 
fluorocitrate than SK-MEL-28 (Figure 5E). This result was con-
firmed by anchorage-independent growth assays in response 
to fluorocitrate, as SK-MEL-19 cell line developed fewer and 
smaller colonies than SK-MEL-28 cell line (Figure 5F and G and 
Supplementary Figure S2, available at Carcinogenesis Online). 
Altogether, these results suggest that reduced ACO1 level and 
activity induced by copy number reductions at the ACO1 locus 
might be responsible for the greater susceptibility to the treat-
ment with fluorocitrate also in melanoma.
Discussion
Two seminal papers outlined the potential of collateral lethality 
to treat specific types of cancers. The first one experimentally 
focused on the deletion of the glycolytic gene ENO1 as a pas-
senger gene in the 1p36 deletion, which is compensated by 
ENO2 expression (7). Five years later the same team returns to 
the synthetic lethality strategy by reporting a clear example of 
collateral lethality featured by the genomic deletion of the gene 
encoding the ME2 in a common deletion involving the tumor 
suppressor SMAD4 in pancreatic ductal carcinoma (16).
In the present paper, we focused on the ACO1 gene as a can-
didate passenger gene in the common 9p21 deletion in T-cell 
lymphoblastic neoplasia. ACO1 is a housekeeping gene that 
encodes a protein able to catalyze the conversion of citrate to 
isocitrate in the cytoplasm and to control the levels of iron in-
side the cells (UniProtKB/Swiss-Prot ACOC_HUMAN, P21399). 
Two paralog genes (ACO2 and IREB2) show partial redundancy 
with the ACO1 gene. The ACO2 gene (at 22q13.2) encodes a 
mitochondrial protein that catalyzes the interconversion of 
citrate to isocitrate via cis-aconitate in the second step of the 
Tricarboxylic acid cycle (UniProtKB/Swiss-Prot for ACO2 gene 
ACON_HUMAN, Q99798). IREB2 (at 15q25.1) encodes an RNA-
binding protein without catalytic activity, which binds to iron-
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Figure 2. Evaluation of the effects caused by fluorocitrate treatment. (A) Flow cytometry analysis of fluorocitrate-treated cells stained with propidium iodide (PI). Cell 
lines were treated with fluorocitrate (25–500 µM) for 24, 48 and 72 h. (B) MTT assays following fluorocitrate treatment are represented as the normalized data of the 
Optical Density (OD) ratio between 560/750 nm. (C) Comparison of cell-viability tests among cell lines. Cells treated with 50 µM (PI staining, left) or 25 µM (MTT assay, 
right) fluorocitrate were compared at 72 h. (D) Apoptotic induction was evaluated by western blot in cell lines treated with fluorocitrate (25–500 µM). Representative 
western blots of Caspase 3 activation and PARP proteolysis. NT: non-treated cells. Data represent the mean (A and B) or median (C) ± standard deviation (SD) of at 
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its mRNA translation. The binding of this protein to the trans-
ferrin receptor mRNA inhibits the degradation of this otherwise 
rapidly degraded mRNA (UniProtkb/Swiss-Prot for IREB2 gene 
IREB2_HUMAN, P48200).
Interestingly, multiple knockout investigation in yeast re-
vealed that ACO1 and ACO2 single knockouts are viable but 
the double knockout condition is lethal (28). In mice, homozy-
gous disruptions of the Aco1 gene display no obvious pheno-
typic abnormalities (MGI: 87879-aconitase 1)  and homozygous 
disruptions of Ireb2 are viable in spite of some behavioral ab-
normalities and nervous system degeneration (MGI: 1928268). 
Combined lethality has been reported for Aco1 and Ireb2 genes 
(29).
Given these precedents, we focused on deletions at the 9p21 
region, a common feature in T-cell lymphoblastic neoplasia. 
Apparently, the primary oncogenic target of these deletions is 
the suppressor gene CDKN2A, but they also mobilized other pas-
senger genes within the deleted site such as ACO1. The analysis 
Figure 3. Ectopic expression of ACO1 in SUP-T1 cells and silencing of ACO1 in JURKAT cells. Changes in ACO1 levels were confirmed 48 h after transfection by western 
blot with ACO1 and FLAG antibodies (A). NEG, SUP-T1 cells harboring the empty vector; ACO1-FLAG, SUP-T1 cells expressing the same vector harboring ACO1 cDNA. 
A representative western blot image is shown. (B) shRNA-CN, JURKAT cells harboring the control vector; shRNA-3 and shRNA-4, JURKAT cells expressing the same 
vector harboring shRNAs against ACO1. A representative western blot image is shown and the numbers depicted below represent the result of densitometry ana-
lysis respect to CN. (C and D) MTT assays 24 h after fluorocitrate treatment (25–500 µM). Data represent the normalized values of the Optical Density ratio between 
560/750 nm. NT: non-treated cells. Data represent the mean ± standard deviation (SD) of at least three independent experiments normalized with respect to vehicle 
(0 µM). Significant differences with respect to NEG (C) and shRNA-CN (D) were determined using Student’s t-test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
Figure 4. Effect of fluorocitrate in xenograft mice harboring SUP-T1 cells. (A) The growth of SUP-T1 subcutaneous tumors in nude mice was evaluated 15 days after 
treatment with fluorocitrate by cellular light emission after d-luciferin injection. Data represent the median average radiance ± standard deviation (SD), normalized to 
vehicle. Significant differences were determined using Student’s t-test (*P ≤ 0.05). (B) Representative images of animals carrying the mentioned tumors, pseudocolored 
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of a panel of cell lines derived from T-cell lymphoblastic neo-
plasia revealed a complex scenario regarding the expression 
levels of the three members of the aconitase multigene family 
(ACO1, ACO2 and IREB2), although the aconitase activity could 
be essentially attributed to the ACO1 protein. Thus, a significant 
decrease in ACO1 expression caused by a deletion in 9p21 would 
Figure 5. Effects of fluorocitrate treatments in melanoma cells with differences in ACO1 copy number, expression and activity. (A) Ideogram of chromosome 9 re-
sulting from microarray-based aCGH analyses in SK-MEL-28 and SK-MEL-19 cells. Partial monosomy of 23.57 Mb (black bar) at the short arm (p22.3-p13.1) was observed 
in SK-MEL-19 cells. This modification affects more than 100 genes including ACO1 (9p21.1). (B) Aconitase expression levels of the three members of the family by 
qRT–PCR. (C) Representative western blots of ACO1, ACO2 and IREB2. Numbers represent the results of densitometry analysis. (D) Cytosolic (ACO1) and mitochondrial 
(ACO2) aconitase activities. One unit indicates the amount of enzyme that will isomerize 1 µM of citrate to isocitrate per minute at pH 7.4 at 25°C. (E) MTT assays after 
fluorocitrate treatment (25 –500 µM). Data represent the normalized data of the Optical Density ratio between 560/750 nm. (F) Soft agar colony formation assay upon 
fluorocitrate treatment (25–500 µM). (G) Representative images of colonies after treatment with fluorocitrate 100 µM. Veh vehicle; FC, fluorocitrate. Data represent the 
mean ± standard deviation (SD) of at least three independent experiments normalized to the average value of SK-MEL-28 and SK-MEL-19 cells (B) or to vehicle (0 µM) (E 
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generate a vulnerability picture in tumor cells, as they would be-
come more sensitive to the treatment with aconitase inhibitors 
like fluorocitrate. Moreover, the effect of this drug should be pro-
portional to the aconitase expression and activity in tumor cells.
Among the cell lines analyzed, SUP-T1 exhibits the lowest 
levels of ACO1 expression and activity and, in addition, it has 
relatively low levels of IREB2 expression. As hypothesized, these 
cells were most susceptible to treatment with fluorocitrate, 
since the aconitase activity was seriously compromised in 
treated cells. Moreover, it could be speculated that the impaired 
iron metabolism in these cells would also contribute to their ex-
haustion upon fluorocitrate treatment.
Given that homozygous 9p21 deletions are common events 
in multiple hematological and solid malignancies, we extended 
our analyses to melanoma. In line with T-cell lymphoblastic 
neoplasia, the reduced levels of ACO1 resulting from 9p21 dele-
tions in SK-MEL-19 also appeared to be a sufficient condition to 
induce vulnerability to fluorocitrate.
The practical suitability of fluorocitrate as a new treatment to 
eliminate tumor cells could be handicapped due to its reported 
high toxicity. However, in vivo experiments in this paper re-
vealed that cells exhibiting ACO1 deficiency (SUP-T1 cells) were 
highly sensitive to the treatment with low doses of fluorocitrate 
(10–100  µM). Kidney injury is one of the main markers of 
fluoroacetate (‘compound 1080’, a fluorocitrate precursor used 
in pest control) toxicity (30). Extensive kidney studies revealed 
no signs of tubular coagulative necrosis in our mice.
Our findings extend the proposal by Mavrakis et al. (14) and 
Kryukov et al. (15) about collateral vulnerability generated by loss 
of MTAP passenger gene in cancers exhibiting the 9p21 deletion, 
by adding ACO1 as another passenger gene sustaining this kind 
of tumor vulnerabilities. Taken together, our results suggest that 
ACO1 protein deficiency, which results from the 9p21 deletion 
or another alternative mechanism, generates a vulnerability in 
tumor cells that can be harnessed to eliminate them by treat-
ment with aconitase inhibitors, while maintaining cell viability 
of the unaffected surrounding tissues.
An apparent weakness of our proposal is that only a small 
number of patients with T-cell lymphoblastic neoplasms could be 
beneficiaries of this treatment. In our limited cohort, 1/19 (5.3%) 
patients exhibited ACO1 deletion. However, 9p21 deletions are 
a fairly frequent event in various hematologic and solid tumors 
(including melanoma, breast cancer, colorectal carcinoma and 
so on). We have performed a search by interrogating cBioPortal 
for tumors with 9p21 deletions involving ACO1. Interestingly, 
3.3% (25/764) of pediatric B-ALL, 0.6% (5/838) of melanoma pa-
tients and 0.3% (41/13343) of patients with breast or lung cancer 
show deletions that involve ACO1 and, consequently, it could be 
deduced that they show significant decreases in the expression 
of ACO1. This indicates that the frequency of ACO1 deletion in 
T-LBL that we have obtained in our limited cohort is represen-
tative of the overall frequency in other cancer types, when ana-
lyzed in much larger cohorts as those included in cBioportal. 
Most interestingly, the number of cancer patients potentially 
candidate to benefit from the treatment with fluorocitrate rises 
significantly beyond those with T-LBL.
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